Stay updated with breaking news from Final Written Decisions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On May 17, 2024, Regeneron filed a second infringement litigation against Celltrion's proposed EYLEA® (aflibercept) biosimilar CT-P42, Case No. 1:24-cv-00053 (N.D.W. Va.).
Chen, J. The Court reversed in part and affirmed in part the Final Written Decisions of the Patent Trial and Appeal Board ("Board") finding unpatentable certain claims of the challenged patents. IOENGINE appealed...
In March, the PTAB cancelled 458 (75.21%) instituted claims across 31 IPR and PGR Final Written Decisions...
Antibody-drug conjugate (ADC) is a promising class of cancer treatments with accelerating U.S. Food and Drug Administration (FDA) approval and rapidly growing market size as discussed...
Late last year, , the United States International Trade Commission (ITC) announced that it would issue a limited exclusion order (LEO) and cease and desist order (CDO) against Apple, Inc. prohibiting Apple from importing and selling its Apple Watch (Series 6 and 7) products in the United States.